SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
7.86
-0.17 (-2.12%)
At close: Nov 13, 2026, 4:00 PM EST
7.81
-0.05 (-0.68%)
After-hours: Nov 13, 2026, 7:59 PM EST
SELLAS Life Sciences Group Employees
SELLAS Life Sciences Group had 13 employees as of December 31, 2025. The number of employees decreased by 2 or 13.33% compared to the previous year. That makes SELLAS Life Sciences Group the 39,723rd largest employer in the world and 5,887th in the United States.
Employees
13
Change (1Y)
-2
Growth (1Y)
-13.33%
Revenue / Employee
n/a
Profits / Employee
-$2,750,846
Market Cap
1.60B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | -2 | -13.33% |
| Dec 31, 2024 | 15 | -1 | -6.25% |
| Dec 31, 2023 | 16 | -1 | -5.88% |
| Dec 31, 2022 | 17 | 6 | 54.55% |
| Dec 31, 2021 | 11 | 4 | 57.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Immunocore Holdings | 524 |
| Vir Biotechnology | 367 |
| Nurix Therapeutics | 317 |
| uniQure | 221 |
| Precigen | 160 |
| Rapport Therapeutics | 84 |
SLS News
- 2 days ago - SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 days ago - SELLAS Life Sciences Group Quarterly report: Q3 2026 - Filings
- 2 days ago - SELLAS Life Sciences Group Earnings release: Q3 2026 - Filings
- 10 days ago - SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 - GlobeNewsWire
- 17 days ago - Sellas Life Sciences falls -17.7% - TheFly
- 17 days ago - SELLAS Life Sciences Stock (SLS) Slides 18% as a Phase 3 Study Enters Its Evaluation Period - TipRanks
- 17 days ago - Sellas Life Sciences triggers final analysis of REGAL trial - TheFly
- 17 days ago - SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia - GlobeNewsWire